It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Lactate accumulation and acidification in tumours are a cancer hallmark associated with the Warburg effect. Lactic acidosis correlates with cancer malignancy, and the benefit it offers to tumours has been the subject of numerous hypotheses. Strikingly, lactic acidosis enhances cancer cell survival to environmental glucose depletion by repressing high-rate glycolysis and lactic fermentation, and promoting an oxidative metabolism involving reactivated respiration. We used real-time NMR to evaluate how cytosolic lactate accumulation up to 40 mM and acidification up to pH 6.5 individually impact glucose consumption, lactate production and pyruvate evolution in isolated cytosols. We used a reductive cell-free system (CFS) to specifically study cytosolic metabolism independently of other Warburg-regulatory mechanisms found in the cell. We assessed the impact of lactate and acidification on the Warburg metabolism of cancer cytosols, and whether this effect extended to different cytosolic phenotypes of lactic fermentation and cancer. We observed that moderate acidification, independently of lactate concentration, drastically reduces the glucose consumption rate and halts lactate production in different lactic fermentation phenotypes. In parallel, for Warburg-type CFS lactate supplementation induces pyruvate accumulation at control pH, and can maintain a higher cytosolic pyruvate pool at low pH. Altogether, we demonstrate that intracellular acidification accounts for the direct repression of lactic fermentation by the Warburg-associated lactic acidosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 University of Lyon, Université Claude Bernard Lyon 1, Laboratoire CarMeN, UMR INSERM U1060/INRAE U1397, Pierre-Bénite, France (GRID:grid.7849.2) (ISNI:0000 0001 2150 7757); University of Lyon, Université Claude Bernard Lyon 1, Master de Biologie, École Normale Supérieure de Lyon, Lyon Cedex 07, France (GRID:grid.7849.2) (ISNI:0000 0001 2150 7757)
2 University of Lyon, Université Claude Bernard Lyon 1, Laboratoire CarMeN, UMR INSERM U1060/INRAE U1397, Pierre-Bénite, France (GRID:grid.7849.2) (ISNI:0000 0001 2150 7757); University of Lyon, Université Claude Bernard Lyon 1, Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, ICBMS UMR 5246, Lyon, France (GRID:grid.25697.3f) (ISNI:0000 0001 2172 4233)
3 University of Lyon, Université Claude Bernard Lyon 1, Laboratoire CarMeN, UMR INSERM U1060/INRAE U1397, Pierre-Bénite, France (GRID:grid.7849.2) (ISNI:0000 0001 2150 7757)
4 University of Lyon, Université Claude Bernard Lyon 1, Institut des Sciences Analytiques, UMR5280 CNRS, Villeurbanne, France (GRID:grid.7849.2) (ISNI:0000 0001 2150 7757)
5 University of Lyon, Université Claude Bernard Lyon 1, Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, ICBMS UMR 5246, Lyon, France (GRID:grid.25697.3f) (ISNI:0000 0001 2172 4233)